Serum Amyloid A is a Novel Inflammatory Biomarker in Polycystic Ovary Syndrome

BACKGROUND: Serum amyloid A (SAA) is considered a biomarker of inflammation; however, the SAA levels in polycystic ovary syndrome (PCOS) are still uncertain. METHODS: In this study, SAA, glucose, insulin, C-reactive protein (CRP), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and total testosterone concentrations were measured in 82 women with PCOS and 60 healthy controls. RESULTS: The median concentration of SAA was 5.000 mg/L (IQR: 2.825 - 5.400) in women with PCOS, which was significantly higher than that of controls (3.700 mg/L, IQR: 2.825 - 5.400, p = 0.025). SAA was only positively associated with the CRP (r = 0.303, p = 0.006). No significant association was observed between SAA and body mass index (BMI), total testosterone, or insulin resistance (IR). CONCLUSIONS: SAA levels were increased in women with PCOS, and SAA may be a potential inflammatory biomarker for PCOS.